A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Clinical trial NCT06627647 · RECRUITING

Trial details

NCT number: NCT06627647
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-squamous Non-small Cell Lung Cancer

Start date: 2024-11-27
Primary completion: 2030-11-18
Enrollment: 1160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.